Pemigatinib generics

The original drug of Pemigatinib (Pemigatinib) has been launched in many countries. It is understood that there are also many countries overseas that produce generic drugs of Pemigatinib. Its pharmaceutical ingredients are basically the same as those of the original drug, and it is suitable for the treatment of F GFR2 genomic abnormalities (such as fusions and rearrangements) are used to treat previously treated, unresectable locally advanced or metastatic cholangiocarcinoma (CCA). There may be slight differences in production specifications and prices. Common generic drug manufacturers include Laos Nanta Pharmaceuticals, Lucius Pharmaceuticals, etc.

An open-label Phase II trial of pemetinib was conducted in 146 patients who had previously received treatment for locally advanced or metastatic cholangiocarcinoma. The majority (107) of patients had FGFR2 alterations. After a median follow-up of 17.8 months, 35.5% of patients in this group responded to treatment. The median duration of response was 7.5 months and the median progression-free survival was 6.9 months. At the time of publication of the trial, the median overall survival was 21.1 months.

The original drug Pemetinib has been launched in China. Due to its short time on the market, it has not yet entered the scope of medical insurance. The price of each box of 9mg*14 tablets may be around 50,000 yuan, which is expensive. The original drug Pemetinib currently on the market overseas, with a specification of 13.5mg*14 tablets, may cost around RMB 70,000 per box (the price may fluctuate due to exchange rates). There are also generic pemetinib drugs produced in other countries overseas, and their drug ingredients are basically the same as those of the original drugs sold abroad. For example, the price of 4.5mg*14 tablets per box produced by a Laos pharmaceutical factory may be around 1,000 yuan (the price may fluctuate due to exchange rates).